Sanofi

News

Sanofi to acquire Kiadis and NK cell tech for $353 million

Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million).

News

FDA sets Feb decision date for Libtayo lung cancer challenge...

The FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), based on data they hope will carve out a niche

News

SparingVision raises €44.5m for retinitis pigmentosa gene th...

French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare ocular disease.

News

Coronavirus vaccine: how pharma is picking up the pace

Sanofi preps trials of second COVID-19 shot, as Russia appro...

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclini

News

Sanofi/Regeneron's Libtayo set for new skin cancer use

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in a hard to treat group of skin can

News

Roche's Actemra cuts chances of COVID-19 ventilator use in p...

Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumo

Sanofi to acquire Kiadis and NK cell tech for $353 million

FDA sets Feb decision date for Libtayo lung cancer challenge...

SparingVision raises €44.5m for retinitis pigmentosa gene th...

Sanofi preps trials of second COVID-19 shot, as Russia appro...

Sanofi/Regeneron's Libtayo set for new skin cancer use

Roche's Actemra cuts chances of COVID-19 ventilator use in p...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Sanofi

Editor's Picks